These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20211150)

  • 1. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".
    Sharma SV; Settleman J
    Biochem Pharmacol; 2010 Sep; 80(5):666-73. PubMed ID: 20211150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted cancer therapeutics.
    Hait WN; Hambley TW
    Cancer Res; 2009 Feb; 69(4):1263-7; discussion 1267. PubMed ID: 19208830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.
    Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Saavedra E; Moreno-Sánchez R
    Mol Aspects Med; 2010 Apr; 31(2):145-70. PubMed ID: 20206201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.
    Gerspach J; Wajant H; Pfizenmaier K
    Results Probl Cell Differ; 2009; 49():241-73. PubMed ID: 19142623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy.
    Zhang E; Zhang C; Su Y; Cheng T; Shi C
    Drug Discov Today; 2011 Feb; 16(3-4):140-6. PubMed ID: 21182981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development and testing of aptamers for cancer.
    Barbas AS; White RR
    Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular therapeutics in patients with cancer unresponsive to conventional treatments].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Gac Med Mex; 2008; 144(4):333-44. PubMed ID: 18942268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing cancer drug discovery towards more agile development of targeted combination therapies.
    Carragher NO; Unciti-Broceta A; Cameron DA
    Future Med Chem; 2012 Jan; 4(1):87-105. PubMed ID: 22168166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting transcription factors for cancer therapy.
    Frank DA
    IDrugs; 2009 Jan; 12(1):29-33. PubMed ID: 19127502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
    Weinstein IB; Joe AK
    Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.